Table 1.
Baseline characteristics of the exploratory and replication cohorts
| Baseline characteristic |
Exploratory population (n = 200) |
Replication population (n = 628) |
|---|---|---|
| Age (years) | 49 (42–57) | 49 (42–56) |
| Sex (male; n, %) | 123 (62%) | 400 (64%) |
| Prednisolone (n, %) | 100 (50%) | 313 (50%) |
| Infection | 21 (11%) | 86 (14%) |
| GI bleeding | 13 (7%) | 63 (10%) |
| Hemoglobin (g/L) | 104 (89–120) | 107 (95–120) |
| Platelets (×109/L) | 114 (70–171) | 111 (77–166) |
| White cell count (×106/mm3) | 8.9 (6.0–12.7) | 8.6 (6.1–12.3) |
| Neutrophils (×106/mm3) | 6.2 (4.0–10.1) | 5.9 (4.1–9.4) |
| INR | 1.9 (1.6–2.2) | 1.7 (1.5–2.0) |
| Bilirubin (μmol/L) | 317 (192–451) | 250 (154–394) |
| Albumin (g/L) | 25 (21–29) | 25 (21–30) |
| ALT (IU/L) | 42 (30–62) | 42 (29–61) |
| AST (IU/L) | 121 (84–171) | 120 (87–161) |
| Sodium (mmol/L) | 134 (129–136) | 134 (131–137) |
| Urea (mmol/L) | 3.8 (2.4–6.9) | 3.2 (2.1–4.9) |
| Creatinine (μmol/L) | 67 (53–104) | 63 (52–79) |
| Prognostic scores | ||
| DF | 60 (48–79) | 54 (42–71) |
| MELD | 24 (22–29) | 23 (21–26) |
| GAHS | 9 (8–10) | 8 (7–9) |
| Mortality | ||
| Day 28 (n, %) | 51 (26%) | 66 (11%) |
| Day 90 (n, %) | 70 (35%) | 126 (20%) |
Data are presented as median and interquartile range. Baseline serum parameters were available in 828 patients, who were randomly divided into the exploratory and replication subgroup.
ALT, alanine transaminase; AST, aspartate transaminase; DF, discriminant function; GAHS, Glasgow alcoholic hepatitis score; GI, gastrointestinal; INR, international normalized ratio; MELD, model for end-stage liver disease.